Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P, Stastna D, Tesar A, Menkyova I, Posova H, Koprivova H, Mikulova V, Hrdy J, Smela G, Horakova D, Rysankova I, Doleckova K, Tyblova M.
Nytrova P, et al. Among authors: mikulova v.
Front Immunol. 2023 Jun 16;14:1149629. doi: 10.3389/fimmu.2023.1149629. eCollection 2023.
Front Immunol. 2023.
PMID: 37398654
Free PMC article.